Why take this course?
AI-enabled systems are increasingly used across pharmaceutical, biotechnology, medical device, and advanced therapy operations for manufacturing support, investigations, process monitoring, document generation, supplier oversight, risk assessment, and other GMP activities. Unlike conventional software, these systems may rely on large training datasets, produce probabilistic outputs, adapt over time, and experience drift or performance degradation. These characteristics create governance and validation challenges that fixed-logic approaches may not fully address.
This webinar examines how EU GMP Annex 22 can structure oversight of AI systems across validation traceability, lifecycle management, data integrity, accountability, and inspection readiness. Participants will consider training data controls, source reliability, output verification, auditability, model monitoring, retraining, change management, supplier qualification, and human decision responsibility. The emphasis is on maintaining evidence of continued fitness for intended use while integrating AI controls into established quality systems and operational processes throughout the operational system lifecycle.
Key Areas Covered
Charles H. Paul
Charles H. Paul has more than 30 years of experience supporting regulated organizations in GMP compliance, quality systems, validation programs, computerized systems oversight, technical documentation, risk management, and inspection readiness. His work aligning regulatory expectations with operational controls directly supports the governance, traceability, data integrity, and lifecycle challenges addressed in this webinar.
Commonly Asked Questions About This Subject
How can an organization demonstrate that AI governance is functioning effectively rather than existing only as documented policy?
Inspection discussions often move quickly beyond governance documents and focus on how decisions are made during routine operations. Policies, organizational charts, and committee structures provide limited assurance if day-to-day activities do not consistently reflect them.
Reviewers frequently examine recent AI-related changes, investigations, deviations, model updates, performance reviews, and risk assessments to determine whether governance is influencing operational decisions. Gaps become visible when responsibilities are unclear, approvals occur without meaningful evaluation, or significant AI-related activities proceed outside established quality processes.
Evidence carrying greater weight includes documented governance decisions, records of periodic performance review, traceable approval of model changes, investigation of unexpected outputs, and management actions taken when performance concerns emerged.
Governance becomes much easier to defend when it consistently influences operational behavior instead of serving primarily as administrative documentation supporting regulatory expectations.
What makes validation traceability for AI systems difficult to maintain throughout the operational lifecycle?
Validation traceability becomes increasingly difficult when organizations treat validation evidence as static while the surrounding operating environment continues to change. Data sources, business processes, interfaces, software components, intended uses, and supporting models may all evolve over time even though the original validation remains formally approved.
Inspection concerns often arise because individual changes appear adequately managed in isolation while cumulative effects gradually weaken traceability between requirements, testing, operational performance, and ongoing system suitability.
Documentation becomes difficult to defend when reviewers cannot easily connect current system behavior to the evidence supporting its original acceptance. Missing links frequently emerge after multiple software updates, retraining activities, process modifications, or infrastructure changes.
Strong lifecycle management preserves clear relationships between validated requirements, implemented functionality, operational monitoring, change history, and continuing evidence demonstrating that the system remains fit for its intended GMP use.
When should changes to training data be treated as quality system changes rather than routine operational activities?
A practical decision point arises when updated training data could reasonably influence how the AI system performs within regulated operations. The concern extends beyond whether new information was added and focuses instead on whether the system's behavior, recommendations, classifications, or analytical performance could change as a result.
Inspection friction develops when organizations manage training data as an information technology activity without evaluating its potential quality impact. Reviewers frequently ask how changes were assessed, what performance was re-examined, and what evidence demonstrates continued suitability after the update.
Documentation becomes more persuasive when the organization records why the training data changed, how associated risks were evaluated, what verification activities were performed, and why existing validation evidence remains sufficient or requires expansion.
Those records demonstrate that changes to training data receive the same disciplined evaluation expected for other GMP-relevant modifications.
What creates the weakest inspection position when AI-generated content becomes part of GMP documentation?
A documentation concern develops when AI-generated information enters controlled records without preserving evidence of how its accuracy, completeness, and suitability were evaluated. Reviewers generally place greater emphasis on the organization's review process than on the technology used to generate the content.
Inspection questions often arise after discovering technical reports, investigations, procedures, risk assessments, or validation records containing statements that cannot be traced to supporting evidence. Those situations become increasingly difficult to explain if documentation simply reflects acceptance of generated content without recorded evaluation.
Evidence supporting stronger control includes documented review criteria, verification against authoritative source information, clear attribution of supporting evidence, records of identified corrections, and traceability showing how final approved content was established.
Organizations generally maintain a stronger regulatory position when generated content becomes the starting point for documented evaluation rather than the final version accepted into the quality system.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.


